Study Evaluating AGG-523 in Subjects With Osteoarthritis

Completed · Phase 1

Conditions studied: Osteoarthritis

In brief

This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.

Key facts

Study ID

NCT00427687

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

Starts

2007-02-01

Expected to finish

2007-06-01

Last updated by the study team

2008-08-05

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Anaheim, California, United States
• Study site — Miami, Florida, United States
• Study site — Altoona, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.